Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span

L. Ashley Watson,1,2 Lauren A. Solomon,1,2 Jennifer Ruizhe Li,1,2 Yan Jiang,1,2 Matthew Edwards,1,2 Kazuo Shin-ya,3 Frank Beier,1,4 and Nathalie G. Bérubé1,2

1Children’s Health Research Institute, London, Ontario, Canada. 2Departments of Paediatrics and Biochemistry, Schulich School of Medicine and Dentistry, Western University, Victoria Research Laboratories, London, Ontario, Canada. 3National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan. 4Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Human ATRX mutations are associated with cognitive deficits, developmental abnormalities, and cancer. We show that the Atrx-null embryonic mouse brain accumulates replicative damage at telomeres and pericentromeric heterochromatin, which is exacerbated by loss of p53 and linked to ATM activation. ATRX-deficient neuroprogenitors exhibited higher incidence of telomere fusions and increased sensitivity to replication stress–inducing drugs. Treatment of Atrx-null neuroprogenitors with the G-quadruplex (G4) ligand telomestatin increased DNA damage, indicating that ATRX likely aids in the replication of telomeric G4-DNA structures. Unexpectedly, mutant mice displayed reduced growth, shortened life span, lordokyphosis, cataracts, heart enlargement, and hypoglycemia, as well as reduction of mineral bone density, trabecular bone content, and subcutaneous fat. We show that a subset of these defects can be attributed to loss of ATRX in the embryonic anterior pituitary that resulted in low circulating levels of thyroxine and IGF-1. Our findings suggest that loss of ATRX increases DNA damage locally in the forebrain and anterior pituitary and causes tissue attrition and other systemic defects similar to those seen in aging.

Introduction

Faithful replication of DNA maintains genomic stability, limits the accumulation of cancer-promoting mutations, and can extend life span. Replication stress can occur spontaneously from stalling of the replication machinery as it encounters obstacles on the DNA template, such as DNA lesions, intricate secondary structures, or DNA-bound proteins (1). Impaired progression of the replication machinery can also occur when cells are exposed to exogenous damage or drugs that limit the nucleotide pool, or that cause interstrand crosslinking. The stabilization of paused replication forks to allow restart involves activation of checkpoint signaling to provide the cell extra time to respond (2). Failure to stabilize stalled forks causes fork collapse, a process involving dissociation of the polymerases, exposure of extended single-stranded DNA (ssDNA) regions, improper processing, and DNA breakage. Stalled replication can have serious consequences, such as genomic instability, chromosomal rearrangements from illegitimate recombination events, and reduced cell viability (1). Constitutive heterochromatin, telomeric DNA, and other DNA structures can pose particular challenges to the replication machinery. To overcome such hindrances, specialized factors are required to resolve difficult DNA structures or to promote access of restart pathway proteins to stalled forks (3).

ATRX is a Rad54-like ATP-driven DNA translocase belonging to the Swi/Snf family of chromatin remodelers (4). The biological impact of ATRX mutations in humans appears to vary according to the extent and timing of disruption. In humans, ATRX somatic frameshift and nonsense mutations that completely abolish protein function have been identified in pancreatic neuroendocrine tumors (PanNETs) (5–7), pediatric and adult glioblastomas, and other cancers of the CNS (8–12), underscoring the anti-tumorigenic roles of ATRX. Tumors with ATRX mutations often harbor long telomeres, which are characteristic of the telomere maintenance mechanism known as alternative lengthening of telomeres (ALT) (6, 7, 11, 13, 14). Conversely, hypomorphic inherited mutations of the ATRX gene cause a rare developmental disorder, ATR-X syndrome (OMIM 301040), with diagnostic features of severe cognitive deficits, microcephaly, seizures, short stature, developmental delay, and α-thalassemia, without increased neoplasia incidence (15–17). Thus, inactivating mutations of the ATRX gene during development are likely embryonic lethal, while diminished ATRX activity leads to severe developmental and cognitive abnormalities. ATRX somatic inactivating mutations that arise later and consequently bypass embryonic development appear to drive cancer progression, particularly in the CNS.

The cellular functions of ATRX are not completely clear; however, several lines of evidence point to a role in the maintenance of genomic integrity. Decreasing levels of ATRX by RNA interference induces spindle defects, as well as chromosomal alignment and segregation problems during mitosis and meiosis, and complete loss of ATRX in neuroprogenitor cells (NPCs) can also induce mitotic abnormalities (18–21). Furthermore, ATRX-depleted mouse embryonic stem cells have unstable telomeres (22). The ATRX protein can bind to specific genomic sites, including imprinting control regions and the Rhox5 promoter (23, 24), but is also highly enriched at repetitive regions, including ribosomal DNA repeats, pericentromeric heterochromatin, and telomeric chromatin, where it was proposed to cooperate with DAXX to incorporate the histone variant H3.3 into chromatin (25–29).

In the present report, we demonstrate that ATRX deletion in NPCs causes excessive replication–related DNA damage, which is exacerbated by loss of p53, replication stress–inducing drugs, and telomestatin (TMS), a G-quadruplex (G4) ligand. Unexpectedly, mutant mice lacking ATRX in the forebrain and pituitary had low circulating IGF-1, thyroxine (T4), and glucose levels and displayed...
In the embryonic period, persistent DNA damage can result in the phosphorylation and upregulation of p53 by the ATR/Chk1 or ATM/Chk2 pathways, leading to cell cycle arrest or apoptosis (33, 34). We previously demonstrated that loss of ATRX results in a p53-dependent apoptotic response in cultured primary mouse NPCs and in vivo in the forebrain at E13.5 (18). To determine whether accumulated DNA damage could be the underlying cause of apoptosis, we performed double immunofluorescence of γH2AX and cleaved caspase-3, a marker of apoptotic cells. The majority of cells undergoing apoptosis (i.e., cleaved caspase-3 cells) in the cKO telencephalon also stained positive for γH2AX, indicating that cell death is likely a downstream consequence of DNA damage (Figure 1C). To substantiate this conclusion and examine the role of p53, we generated ATRX/p53 compound mutant mice and assessed levels of DNA DSBs in the brain. γH2AX signal in cKO;p53−/− embryos was increased compared with that in cKO mice, suggesting that the accumulation of DNA damage in the ATRX-deficient forebrain directly triggers a p53-dependent apoptotic response and that the absence of p53 prevents the removal of these cells by apoptosis (Figure 1A and B, right panels and graphs). We next explored the possible involvement of ATR and ATM signaling in the response to increased DNA damage. Western blot analysis of control and cKO E13.5 telencephalon protein extracts demonstrated similar activation of ATR in control and cKO samples. On the other hand, a clear increase in ATM activation was observed in the cKO embryonic telencephalon (Figure 1D). Taken together, these findings show that loss of ATRX in the embryonic brain results in the accumulation of DNA damage, which triggers activation of ATM and p53, culminating in neuroprogenitor cell death.

**DNA damage response at telomeres and telomeric DNA end fusions.** To determine the specific genomic sites of DNA damage response incurred by loss of ATRX, we examined telomeres, since ATRX enrichment has been previously reported at these genomic regions. However, since it has been proposed that ATRX associates with telomeres only in pluripotent embryonic stem cells (22), we first assessed whether ATRX protein is present at telomeres in NPCs. ATRX immunofluorescence performed in conjunction with telomere FISH (Tel-FISH) in control NPCs demonstrated colocalization of ATRX and a subset of telomeres (Figure 2A). Next, we used Tel-FISH in combination with γH2AX immunostaining to determine whether the DNA repair machinery is activated at telomeric chromatin in cultured cKO NPCs. Confocal imaging showed that the number of telomere dysfunction–induced foci (TIFs) per nucleus was increased in the cKO compared with control NPCs (Figure 2B). In fact, 66.1% of all γH2AX foci were observed at telomeres in the cKO cells (Supplemental Figure 2A). These numbers reflect the acrocentric nature of mouse chromosomes, with some γH2AX foci overlapping with the p arm telomere and the adjacent pericentric region. Our results demonstrate that pericentric regions of the genome are prone to DNA damage in the absence of ATRX. To further explore the function of ATRX in genome stability, we examined metaphase spreads from control and cKO NPC cultures. ATRX immunostaining of control metaphase spreads revealed strong enrichment of the protein at pericentric heterochromatin and at some telomeres (Supplemental Figure 2C).
Analysis of DAPI-stained spreads revealed an increased frequency of chromosome fusions in cKO metaphase spreads compared with controls, as evidenced by overlapping chromosomes (Figure 2C). Centromere-to-centromere, centromere-to-q arm, and q arm-to-q arm fusions were observed. The number of chromosomes per metaphase spread was not affected in cKO NPCs (Supplemental Figure 2D). To further explore the nature of the fusions, we performed TelFISH on control and cKO metaphase spreads and detected an increased incidence of telomeric DNA end fusions (Figure 2D). Other common defects included telomere deletions or duplications, as well as merged or bridged telomeres (Figure 2E). Overall, the frequency of all telomere defects

Figure 2
Increased DNA damage and telomere defects in cKO NPCs. (A) Confocal immuno-FISH images of ATRX (red) and telomeres (Tel-FISH; green) in NPCs demonstrates colocalization of the ATRX protein with a subset of telomeres. Scale bar: 5 μm. (B) Confocal immuno-FISH images of γH2AX (red) and telomeres (Tel-FISH; green) shows increased incidence of TIF (γH2AX/Tel-FISH colocalization) in cKO compared with control NPCs (300 nuclei counted, n = 3 control/cKO littermate-matched pairs). Scale bar: 10 μm. (C) DAPI staining of control and cKO metaphase spreads shows representative chromosome fusion in cKO NPC metaphase (arrowhead). Frequency of fusions per metaphase was increased in cKO metaphases compared with control (control: 88 metaphases, cKO: 108 metaphases counted, n = 3). (D) Tel-FISH (green) demonstrates increased telomeric fusions in cKO metaphase chromosomes compared with control (1,475 chromosomes counted; n = 3). (E) Telomere defects (deletion, merge, bridge, and duplication) were scored in control and cKO metaphase chromosomes. Representative images of defects appear to the right of quantification. In all cases, cKO chromosomes showed an increase in telomeric defects compared with control (1,475 chromosomes counted; n = 3). Original magnification, ×1,000 (A and B); ×630 (C–E). *P < 0.05.
Atrx is not required for the repair of DSBs. Accumulation of DNA DSBs could occur if ATRX plays a direct role in DSB repair mechanisms. Two non–mutually exclusive pathways carry out repair of DNA DSBs: homologous recombination (HR) in proliferative cells; and non-homologous end joining (NHEJ) in postmitotic cells (35). Since γH2AX foci were primarily concentrated in proliferative zones of the developing brain, we reasoned that ATRX may be specifically involved in the repair of DSBs via HR. To address this possibility, we cultured primary NPCs for 2 days in N2 neurobasal medium and exposed proliferative NPCs to γ-irradiation to induce DSBs and activate the HR pathway. The DNA damage response (i.e., γH2AX signal accumulation) was measured between 0 and 6 hours after irradiation, when damage induced by low doses of γ-irradiation should be actively resolved in control cells (Supplemental Figure 3). Both control and cKO NPC colonies showed a dose-dependent increase in γH2AX signal 3 hours after irradiation, which was subsequently resolved (i.e., decreased γH2AX staining) by 6 hours after treatment (Supplemental Figure 3). Therefore, we concluded that ATRX is not required for repair of exogenous radiation–induced DSBs.

ATRX protects cells from replication stress. Since ATRX does not appear to function in the repair of DSBs, we reasoned that it might help prevent DNA damage to preserve genomic integrity. Given that damage is restricted to proliferating regions of the cKO embryonic brain, we tested the possibility that cKO NPCs are particularly sensitive to DNA damage during S phase. We inactivated ATRX in Atrx-deficient mouse embryonic fibroblasts (MEFs) with adenoviral delivery of Cre recombinase and treated them with hydroxyurea (HU), a drug that depletes deoxyribonucleotide pools, inhibits DNA synthesis, and causes replication fork stalling (36). MEFs were treated with increasing doses of HU for 24 hours, and cell viability was assessed 2 days later. MEFs lacking ATRX (Ad-CreGFP) were more sensitive to HU than untreated cells or cells treated with Ad-GFP. Ad-CreGFP treated MEFs were not more sensitive to γ-irradiation than Ad-GFP–transduced or untransduced cells (Figure 3A). We also treated control and cKO NPCs with HU and mitomycin C (MMC), a DNA crosslinker that also causes replication fork stalling. Both HU and MMC treatment caused decreased viability of cKO NPCs compared with control cells. As in MEFs, exposure to various doses of γ-irradiation did not alter cKO NPC viability compared with control NPCs, demonstrating a specific sensitivity to drugs that induce replication fork stalling (Figure 3B).

Blocked replication forks could be a source of genomic instability in the cKO cells, since they can lead to collapse of the reiposome and the formation of DSBs (37). Replicating cortical NPCs lacking ATRX protein were assessed for DNA damage (γH2AX) at replication foci using an anti-PCNA antibody and imaged using confocal microscopy (Figure 3C). PCNA is a component of the replication machinery and exhibits a distinct staining pattern during S phase. In late S phase, the replication foci are observed in regions of the nucleus containing heterochromatin and as such colocalize with DAPI-bright heterochromatin bundles (38). Atrx-null NPCs accumulated more DNA damage at these late replication foci compared with control cells, confirming an increase in DSBs during the replication process (Figure 3C). We also performed FACS analysis to determine whether S phase is extended in these cells. We detected a small but significant decrease in the G1 population and a modest increase in S phase population in the cKO NPCs at 4 days in vitro. This suggests that difficulties in replicating heterochromatin result in a slight delay in S phase progression of cKO cells (Supplemental Figure 3B). We conclude from these findings that loss of ATRX results in an accumulation of endogenous replicative damage in cultured NPCs, specifically at late-replicating chromatin.

G4-DNA stabilization exacerbates DNA damage and decreases viability of Atrx-null NPCs. A potential function of ATRX is to stabilize stalled forks or facilitate the replication of complex secondary DNA structures, such as G4-DNA, which are found at telomeres, among other genomic sites (39). To test whether ATRX facilitates the replication of G4-DNA, we treated control and Atrx-null NPCs with TMS, a natural product isolated from Streptomyces anulatus that binds with high affinity to G4 structures (40). Neuroprogenitors dissected from control and cKO embryonic forebrain were cultured and treated with 20 μM TMS for 24 hours. γH2AX staining was increased (Figure 3D), and cell viability was decreased (Figure 3E) in the TMS-treated cKO NPCs compared with TMS-treated control cells. These findings suggest that ATRX deficiency in NPCs synergizes with G4-DNA stabilization to cause DNA damage and cell death.

Loss of ATRX shortens life span and induces progeroid-like phenotypes. While a portion of mutant pups die in the neonatal period (30), many cKO mouse survived, but rarely longer than 30 days after birth (P30), with an average life span of 22.7 ± 1.7 days (Figure 4A). Moistening of food pellets to help with intake of solids did not improve life span, nor did the removal of siblings from the litter to reduce competition for breast milk (Figure 4A). Mutant mice at P20 had milk in the stomach, suggesting that starvation was not the cause of death or growth retardation. P17 cKO mice had severely stunted growth compared with control littermates, as determined by measurements of body weight and length, as well as length of various skeletal elements (Figure 4, B–E). Reduced body size was apparent at birth (30), but a more dramatic effect was seen from P5 onward. The tibia, femur, humerus, radius, ulna, and foot were significantly shorter in the cKO mice at P17 (Figure 4E). We confirmed specific deletion of ATRX in the forebrain of cKO mice at several postnatal time points, while ATRX remained expressed in other tissues, such as the liver, heart, thymus, spleen, testes, and skeletal growth plate of cKO mice (Supplemental Figure 4, A–D).

Microcomputed tomography (microCT) analyses showed that cKO mutant mice displayed kyphosis, an abnormal curvature of the spinal column (Figure 5A), as well as decreased bone mineral density (BMD), lower trabecular number, and reduced bone cortical thickness (Figure 5, A–D). Loss of trabecular bone was confirmed by picrosirius red staining of tibia, femur, and humerus of control and cKO mice at P17 (Figure 5E). To determine whether this effect stemmed from a developmental problem or was due to tissue degeneration, we also assessed trabecular bone at earlier ages. We found no difference in neonatal and P7 mice and detected an intermediate phenotype at P10, suggesting that bone development occurs initially normally, with evidence of deterioration from P10 onward (Supplemental Figure 5A).

Extensive loss of subcutaneous fat (<25% of controls) was a constant characteristic of the mutant mice, while thickness of the dermis was not significantly affected (Figure 5F). Again, by measuring subcutaneous fat at various time points, we observed that this phenotype was exacerbated at P20 compared with P10 (Supplemental Figure 5, B and C). Mutant mice rarely opened their eyes, and analysis of the lens showed the formation of cataracts (Figure 5G). Accounting for decreased total body weight of the cKO mice, the spleen and liver were consistently smaller and the heart was signifi-
Figure 3
ATRX-deficient cells are hypersensitive to replication stress–inducing agents and the G4-DNA ligand TMS. (A) AtrxloxPloxMEFs were untransduced or transduced with adenovirus expressing Cre recombinase fused to GFP (Ad-CreGFP) or Ad-GFP and subsequently treated with HU for 24 hours or γ-irradiated at the indicated doses. Cell viability was measured at 24 hours after HU treatment (n = 4) and at 6 hours after irradiation (n = 3) via trypan blue dye exclusion. (B) Control and cKO NPCs were treated with HU or MMC for 24 hours or γ-irradiated at the indicated doses. Cell viability was measured at 24 hours after HU and MMC treatment and at 6 hours after irradiation (n = 3). (C) Co-immunofluorescence detection of PCNA, a marker of replication foci, and γH2AX in control and cKO E13.5 cortical cryosections. Results were quantified by measuring the ratio of γH2AX staining that localized to late-replicating PCNA foci to total γH2AX staining per cell, to account for overall lower levels of γH2AX signal in control cells (300 nuclei counted, n = 3). Scale bar: 12 μm. (D) Control and cKO NPCs were treated with 20 μM TMS for 2 hours, and γH2AX signal was imaged 6 hours after treatment. Scale bar: 70 μm. (E) Control and cKO NPCs were treated with TMS for 24 hours, and cell viability was measured 24 hours after treatment (n = 3). Original magnification, ×600 (C); ×100 (D). *P < 0.05.

Discussion
We have shown that ATRX deficiency causes replicative DNA damage at telomeres and pericentromeric heterochromatin and increases the incidence of telomeric fusions. Moreover, deletion of the Atrx gene in the embryonic nervous system and anterior pituitary attenuates postnatal endocrine and metabolic signaling with concurrent growth reduction and progressive progeria-like tissue deterioration. Control experiments confirmed that loss of ATRX is restricted to the forebrain and anterior pituitary. Furthermore, our previous studies have shown that specific and efficient inactivation of the Atrx gene in cartilage does not cause any of the skeletal and growth phenotypes described here (47), providing further evidence that these defects are non-cell-autonomous.

We do not yet fully comprehend the mechanisms responsible for the accumulation of DNA damage observed in the Atrx-null embryonic forebrain and pituitary. We established that loss of ATRX does not prevent DNA repair, since γH2AX foci did not persist in the postnatal brain at P7 and Atrx-null cultured NPCs could resolve DSBs induced by γ-irradiation. However, we provide evidence that the accumulation of damage is partly due to replication stress linked to G4-DNA stability. Telomeres are nucleoprotein complexes that protect chromosome ends from degradation and end fusions. They consist of repetitive DNA high in guanine and cytosine nucleotide residues and have the ability to form G4s when the single-stranded form (39). The presence of these bulky DNA adducts can potentially impede DNA replication. We demonstrate that Atrx-null NPCs are hypersensitive to the potent G4 ligand TMS, suggesting that in the absence of ATRX, cells have difficulty in resolving G4-DNA. This conclusion is supported by the demonstration that the ATRX protein can bind G4-DNA structures in vitro (48). Since G4-DNA structures form at telomeres, the γH2AX signals we observed at telomeres in Atrx-null NPCs may result from a failure to properly resolve G4 structures, leading to telomere...
uncapping and initiation of the DNA damage response. This in turn may explain the increase in telomere fusions observed in Atrx-null NPCs due to repeating break-fusion-break cycles. In contrast, heterochromatic regions flanking centromeres are AT rich, and a role for ATRX in facilitating replication of G4-DNA structures cannot explain the increased genetic damage at these sites. ATRX potentially plays a more general role in heterochromatin remodeling/replication during late S phase or may be required to facilitate replication of other secondary structures. ATRX is associated with the DAXX histone chaperone and was proposed to participate in the incorporation of histone variant H3.3 at highly repetitive regions, including pericentric heterochromatin and telomeric chromatin (28, 49). There is evidence that promyelocytic nuclear bodies (PML-NBs) are involved in facilitating heterochromatin remodeling/replication in late S/G2 phase (50). ATR-X syndrome patient mutations have been shown to alter ATRX targeting to PML-NBs, suggesting an important requirement for ATRX at these subnuclear domains (51). ATRX and DAXX localize to PML-NBs during S phase and may be required for remodeling of heterochromatin during replication, a process likely to involve nucleosome remodeling and histone variant deposition or ejection (52).

An important and unexpected finding from our studies is that specific loss of ATRX early during embryonic brain and pituitary development can influence postnatal health and life span. Systemic loss or mutation of several factors required for telomeric stability, response to replication stress, or nucleotide excision repair (NER) cause phenotypes that resemble premature aging in mice (44, 53–60) and segmental progeria syndromes in humans, including XPF/ERCC1 in xeroderma pigmentosum, ERCC6/8 in Cockayne syndrome, and ATR in Seckel syndrome (61).

The link between excessive DNA damage and a suppressed IGF-I response, although reported in many progeria models, has not yet been satisfactorily explained. Here, we provide evidence that DNA damage in the embryonic pituitary leads to decreased expression of Tsh, with the predictable outcome of low thyroxine production by the thyroid. Recent reports have demonstrated that thyroid hor-

Figure 4
Reduced growth and life span in mice lacking ATRX in the forebrain. (A) Kaplan-Meier survival curve of Cre+ control (n = 12) and cKO mice raised with (+sibs, n = 13) or without (–sibs, n = 11) siblings. Survival of cKO mice was significantly decreased compared with that of control mice (P = 0.0001). The survival of cKO mice was not significantly different whether they were raised with or without siblings (P = 0.4974). (B) Representative pictures of P17 control and cKO littermates, illustrating size difference of the mice. (C) Body weight (g) and length (cm) measurements of control (Cre+, n = 25; Cre+, n = 8) and cKO (n = 24) mice. No significant difference was observed between Cre+ and Cre+ control mice. (D) Skeletal elements of control and cKO mice were stained with alizarin red and alcian blue. (E) Length measurements of P17 control and cKO skeletal elements. (n = 5). *P < 0.05.

research article
mone is more critical than growth hormone in the regulation of IGF-1 levels at prepubertal stages of development (62). Genetically modified mice that are deficient in thyroid hormone show greater than 50% reduction in \( \text{Igf1} \) expression in liver and bone, and T4 treatment can reverse this effect (62). In addition, thyroid hormone and its receptor can bind intron 1 of the \( \text{Igf1} \) gene and stimulate its expression (62). In line with this model, circulating thyroid hormone levels were decreased in the \( \text{Atrx-cKO} \) mice, and several thyroid hormone-responsive genes were decreased in the liver. We also detected altered expression of several genes involved in IGF-1 signaling in the liver, including reduced \( \text{Igals} \) and increased \( \text{Igfbp1} \) expression. Notably, \( \text{Ercc1}^{-/-} \) mice exhibit a quite rapid postnatal degeneration phenotype similar to that of the \( \text{Atrx-cKO} \) mice, and \( \text{Thrsp} \) is the most downregulated gene in the \( \text{Ercc1-null} \) liver, exhibiting a 15-fold decrease (63). This suggests that diminished thyroid hormone action might be implicated in both models, and it will be

**Figure 5**

Postnatal phenotypes in \( \text{Atrx-cKO} \) mice. (A) Whole skeletal isosurface images of P17 control and cKO mice were generated using microCT. Arrow points to kyphosis. Scale bar: 10 mm. (B) Horizontal view of the cKO skull illustrates decreased bone mineralization. Scale bar: 5 mm. (C) Tibial cross section shows decreased cortical thickness. Scale bar: 1 mm. (D) Decreased BMD (*\( P = 0.002 \)), trabecular number (**\( P = 0.002 \)), and cortical thickness (†\( P = 0.0001 \)) in the cKO mice compared with controls. Data were obtained from hind legs using MicroView 3D software (\( n = 3 \)). (E) Picosirius red staining of P17 control and cKO tibia (representative image), femur, and humerus reveals a drastic loss of trabecular bone area in cKO compared with control mice (\( n = 4 \); *\( P < 0.05 \)). Scale bar: 200 \( \mu m \). (F) H&E staining of P20 skin cryosections shows loss of subcutaneous fat in cKO compared with control mice (\( n = 3 \); *\( P = 0.0002 \)). Dermal thickness was not significantly different (\( n = 3 \); *\( P = 0.3545 \)). Scale bar: 300 mm. sf, subcutaneous fat; d, dermis. (G) Dark field image of P20 control and cKO ocular lenses demonstrates appearance of cataracts (loss of lens transparency) in cKO compared with control. (H) Dark field image of P20 control and cKO spleen demonstrates the disproportionally smaller size of cKO spleen. Original magnification, \( \times 50 \) (E and F). See also Supplemental Figure 5.
important in the future to examine thyroxine levels in other models of progeria. Taken together, our findings suggest that DNA damage incurred in the embryonic anterior pituitary leads to defective expression of Tsh postnatally, causing hypothyroidism, decreased IGF-1 signaling, and hypoglycemia. Decreased IGF-1 in the serum can negatively impact skeletal growth development, trabecular content, and subsequent mineralization, as seen in our cKO mice (64). It should be noted that thyroid hormone can also act directly on target tissues such as growth plate chondrocytes, independent of liver-derived IGF-1. Reduced bone growth, and possibly other phenotypes observed in our mutant mice, might therefore be caused by a combination of reduced circulating IGF-1 and reduced thyroid hormone receptor activation in the target tissue (65, 66).

Hyperactivity of the p53 tumor suppressor gene shortens life span and accelerates aging in mice (67). We had previously reported that p53 is activated in the absence of ATRX in the embryonic brain and that loss of p53 rescued cell death in the Atrx-deficient mouse brain (18). Thus, p53 is required for the removal of cells with excessive DNA damage in the Atrx-null brain, which explains the enhanced accumulation of DNA damage we observed upon simultaneous loss of ATRX and p53. Decreased telomere stability and length are also key determinants of life span and have been reported in cancer as well as several types of segmental progeria syndromes, such as Werner syndrome, Cockayne syndrome, dyskeratosis congenita, and Hutchinson-Gilford progeria (68–75). If telomeric damage is the

**Figure 6**

Endocrine defects and hypoglycemia in Atrx-cKO mice. (A) Longitudinal growth of control and cKO tibia was measured after 7 days (d7) of ex vivo culture. Results are expressed as the ratio of length at d7 to that at d0. No difference in growth was detected between control and cKO mice (n = 3). Scale bar: 100 μm. (B) Serum and liver IGF-1 levels are decreased in cKO mice (n = 3). (C) Expression of several IGF-1 pathway genes is altered in cKO liver compared with controls (n = 3). Real-time data were normalized to Gapdh expression. (D) Circulating T4 levels are significantly decreased in P20 cKO mice compared with controls, while GH levels are only mildly affected (n = 3). (E) Thyroid hormone target genes exhibit decreased expression in the liver of P20 cKO mice compared with controls (n = 3). Real-time data were normalized to Gapdh expression. (F) Glucose levels are reduced in P20 cKO serum compared with controls (n = 5). Original magnification, ×50 (A). *P < 0.05.
key driver of life span, our findings would then suggest that telomeric abnormalities confined to specific brain and/or pituitary cells are in themselves sufficient to induce several aging-like phenotypes prematurely, a provocative idea that would have to be confirmed or dismissed in future work.

Problems in replication have been shown to lead to chromosome segregation failures in ensuing mitoses (76). Similarly, several G4-DNA ligands have been demonstrated to cause telomeric fusions and telomere aggregate formation that eventually lead to chromosomal instability, anaphase bridges, and mitotic catastrophe (77–81). It is conceivable that replicative damage is the underlying cause of mitotic defects that we previously reported in ATRX-deficient human cells, such as chromosome missegregation, anaphase bridges, and micronucleus formation (19). Functions for ATRX in restricting replicative stress, telomere fusions, and mitotic defects may also help explain the tumor-suppressive roles recently ascribed to the ATRX protein. Mutations in the ATRX gene were identified in several types of cancers, including pediatric brain tumors (5–7, 9, 10). A common denominator in the majority of Atrx-null tumors was the frequent appearance of large telomeric foci, a hallmark of alternative lengthening of telomeres (ALT), providing further evidence that ATRX function is intimately linked to telomere biology, possibly as a suppressor of illegitimate recombination events. The hypersensitivity of Atrx-
null neuroprogenitors to TMS is an important finding in that regard, as it indicates that Atrx-null tumors may be susceptible to treatment with G4-DNA binding ligands.

Methods

Mouse husbandry, genotyping, and tissue preparation. Mice were exposed to 12-hour light/12-hour dark cycles and fed tap water and regular chow ad libitum. The Atrx<sup>loxP</sup> mice have been described previously (30, 82). Atrx<sup>loxP</sup> mice, when mated to mice expressing Cre recombinase under the control of the Foxg1 promoter (Foxg1<sup>Foxg1<sub>Cre</sub></sup>) (31), produce male progeny (Atrx<sup>loxP/loxP</sup>Foxg1<sup>Foxg1<sub>Cre</sub></sup>) with Atrx deficiency in the forebrain (Atrx<sup>loxP/loxP</sup>). To account for heterozygosity of Foxg1 due to knock-in of the Cre recombinase gene, Cre<sup>+</sup> males were used as controls. T<sup>p53<sup>−/−</sup>/<sup>−</sup></sup> mice were obtained from The Jackson Laboratory, and the mutant allele was introduced into the Atrx<sup>loxP/loxP</sup> and Foxg1<sup>Foxg1<sub>Cre</sub></sup> mice. Subsequent mating of this progeny yielded mice that are p53-null in all tissues and Atrx/p53 double-null in the forebrain. For timed matings, midday of discovery of the vaginal plug was considered to be E0.5. Yolk sac or tail DNA was used for genotyping. Atrx, Cre, and p53 genotyping was performed by PCR as previously described (18, 30).

Immunofluorescence and antibodies. Embryos were fixed overnight in 4% paraformaldehyde, washed 3 times in 1× PBS for 5 minutes each, and dehydrated in 30% sucrose PBS. Postnatal mice were perfused with 4% paraformaldehyde before PBS washes and dehydration. Brains were flash-frozen in liquid nitrogen using CryoMatrix (Thermo Scientific) cryoprotectant and sectioned as described previously (83). For immunofluorescence staining of cryosections, antigen retrieval was performed on slides by microwaving slides in solution for 10 minutes on low. After cooling, slides were dehydrated in 30% sucrose PBS. Postnatal mice were perfused with 4% paraformaldehyde, washed 3 times in 1× PBS for 5 minutes each, and the mutant allele was introduced into the Atrx<sup>loxP/loxP</sup> and Foxg1<sup>Foxg1<sub>Cre</sub></sup> mice. Subsequent mating of this progeny yielded mice that are p53-null in all tissues and Atrx/p53 double-null in the forebrain. For timed matings, midday of discovery of the vaginal plug was considered to be E0.5. Yolk sac or tail DNA was used for genotyping. Atrx, Cre, and p53 genotyping was performed by PCR as previously described (18, 30).

Immunofluorescence and antibodies. Embryos were fixed overnight in 4% paraformaldehyde, washed 3 times in 1× PBS for 5 minutes each, and dehydrated in 30% sucrose PBS. Postnatal mice were perfused with 4% paraformaldehyde before PBS washes and dehydration. Brains were flash-frozen in liquid nitrogen using CryoMatrix (Thermo Scientific) cryoprotectant and sectioned as described previously (83). For immunofluorescence staining of cryosections, antigen retrieval was performed on slides by microwaving slides in solution for 10 minutes on low. After cooling, slides were washed and incubated with primary antibody overnight at 4°C. For detection of PCNA, primary antibody was incubated in 10 U/ml DNAse I (Sigma-Aldrich) as previously described (18). Slides were washed in PBS and incubated with secondary antibody for 1 hour. Sections were counterstained with DAPI (Sigma-Aldrich) and mounted with Vectorshield (Vector Laboratories) or SlowFade Gold (Invitrogen). For immunofluorescence staining of primary cortical culture, cells were incubated in blocking solution (PBS with 0.3% Triton-X and 5% normal goat serum) for 30 minutes and subsequently incubated with primary antibody overnight at 4°C. Cells were washed in PBS and incubated with secondary antibody for 1 hour. Cells were counterstained with DAPI and mounted with Vectorshield.

The following primary antibodies were used: anti-ATRX, rabbit polyclonal (1:200; Santa Cruz Biotechnology Inc.); anti-cleaved caspase-3 (Asp175), rabbit monoclonal (1:400; Cell Signaling Technology); anti-γH2AX (Ser139), rabbit (1:100; Millipore); anti-PCNA, mouse monoclonal (1:100; Santa Cruz Biotechnology Inc.). The secondary antibodies used were goat anti-rabbit—Alexa Fluor 594 (1:800 dilution; Molecular Probes) and goat anti-mouse—Alexa Fluor 488 (1:800 dilution; Molecular Probes).

Microscopy. Experiments demonstrating colocalization of γH2AX and PCNA, γH2AX and major satellite repeats, and γH2AX and telomeres were captured using a laser scanning confocal microscope (FV1000, Olympus). z-Stacks were obtained at 0.25-μm z intervals generally spanning 10–20 μm. Overlapping signal was scored as a colocalization event. For colocalization of γH2AX and PCNA, only cells in which PCNA staining was characteristic of late S phase were counted. Each cell (n = 300) was scored for the number of γH2AX foci that overlapped with PCNA foci divided by the total number of γH2AX foci per cell, to obtain a measure of the cellular levels of DNA damage (γH2AX) at late-replicating chromatin. All other images were captured using an inverted microscope (DMI 6000b, Leica). Digital microcopy images were captured with a digital camera (ORCA-ER, Hamamatsu). Openlab imaging software was used for manual and automated image capture, and processing was performed using Volocity software (PerkinElmer).

For quantification of γH2AX foci per area, at least 6 serial cortical cryosections were assessed for γH2AX foci within the indicated regions. To obtain a relative measure of DNA damage, the ratio of γH2AX foci to area (mm²) was calculated. The same method was used to quantify the ratio of cleaved caspase-3 γH2AX<sup>+</sup> cells, and for this experiment a Student’s t test was used to compare only the proportion of caspase-3 γH2AX<sup>+</sup> cells between control and Atrx-null mice.

Western blot analysis. Nuclear protein was extracted from E13.5 telencephalon using a standard extraction kit (Thermo Scientific) and quantified using a Bradford assay. Protein (10 μg) was resolved on 6% SDS-PAGE and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were probed with anti-ATM, rabbit monoclonal (1:500, Millipore); anti–phospho-ATM (S1981), mouse monoclonal (1:250, Rockland); anti-ATR, goat polyclonal (1:250, Santa Cruz Biotechnology Inc.); anti–phospho-ATR (S428), rabbit polyclonal (1:250, Santa Cruz Biotechnology Inc.); and anti-INCENP, rabbit polyclonal (1:10,000, Sigma-Aldrich) antibodies, followed by the appropriate horseradish peroxidase–conjugated secondary antibodies (1:4,000, GE Healthcare). The membrane was incubated in ECL before exposure to X-ray film. See complete, unedited blots in the supplemental material.

Primary NPC cultures and manipulation. Cortical progenitor cultures were prepared as described previously (84, 85) using cortices dissected from E13.5 embryos. Cells were seeded on polyornithine-coated (Sigma-Aldrich) plastic plates or glass coverslips. Primary cortical cultures were treated with acute γ-irradiation (0, 1, 5, and 10 Gy) 2 days after plating using a Cobalt-60 irradiator (Theratron 60, Atomic Energy of Canada Limited) located in the London Regional Cancer Center, London, Ontario, Canada. Cells were fixed in 4% paraformaldehyde for 10 minutes, washed in PBS, and stored in PBS at 4°C at 0, 3, and 6 hours after treatment and processed for immunofluorescence. HU (Sigma-Aldrich), MMC (Sigma-Aldrich), γ-irradiation, and TMS (synthesized in the Biomedical Information Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo, Japan) sensitivity assays in cultured NPCs were conducted 48 hours after plating cells. NPC cultures were treated with appropriate doses of HU, γ-irradiation, or TMS for the indicated length of time, and cell viability was measured using the trypan blue dye exclusion method. Cell counts were determined with a hemacytometer.

FISH. For DNA-FISH experiments, primary cortical cultures were permeabilized in CSK buffer with 0.5% Triton-X (Sigma-Aldrich) prior to fixation. For TelFISH, a fluorophore-labeled DNA oligonucleotide probe (TAACCC–Alexa 488–3’ (Integrated DNA Technologies), was dissolved at 1 pmol/ml in hybridization buffer. Hybridization was performed as previously described (86). For major satellite FISH, immunofluorescence was performed first, followed by fixation with 4% paraformaldehyde for 10 minutes and subsequent hybridization with a major satellite repeat probe as previously described (87).

MEF cultures and manipulations. E13.5 embryos were minced, digested in trypsin for 45 minutes at 37°C, and resuspended in DMEM (Sigma-Aldrich) containing 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, and 2 μM 1-glutamine. Primary Atrx<sup>loxP/loxP</sup> and wild-type MEFs were seeded at 1.5 × 10<sup>6</sup> cells per 6-well plate and transduced with adenoovirus expressing Cre recombinase and a GFP reporter gene (Ad-CreGFP) or GFP only (Ad-GFP control) approximately 12 hours later. Three days after transduction, MEFs were counted and reseded at 1.5 × 10<sup>6</sup> cells per 6-well plate (P5/P0). HU sensitivity in MEFs was determined by transducing 1.5 × 10<sup>6</sup> cells with adenoovirus, culturing for 72 hours, and treating cells with appropriate doses of HU for 24 hours, replacing medium, and measuring viability via trypan blue dye exclusion 2 days later. Sensitivity to γ-irradiation in MEFs was assessed by transducing 1.5 × 10<sup>6</sup> cells with adenoovirus, waiting 72 hours, and treating cells with appropriate doses of γ-irradiation and measuring viability via trypan blue dye exclusion 48 hours later.
qRT-PCR. Total RNA was obtained from control and cKO liver with the RNeasy Mini Kit (Qiagen) and reverse transcribed into cDNA as described previously (8). Control reactions without reverse transcriptase were prepared in parallel. cDNA was amplified with gene-specific primers under the following conditions: 25–35 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute. For qRT-PCR, cDNA was amplified with qSYBR Green Master Mix (Bio-Rad) by using the standard curve C, method of quantification. Experiments were performed on a Chromo-4 thermocycler (MJ Research) and analyzed with Opticon Monitor 3 and GeneX (Bio-Rad) software. Gene expression analysis was repeated in triplicate for each sample. Conditions for amplification were as follows: 35 cycles of 95°C for 10 seconds, 55°C for 20 seconds, 72°C for 30 seconds, and a final melting curve generated in increments of 0.5°C per plate read. Standard curves were generated for each primer pair with 3-fold serial dilutions of control cDNA. Primer efficiency was calculated as: \( E = \left(10^{-\frac{1}{slope}} - 1\right) \times 100\% \), where a desirable slope is –3.32 and \( r^2 > 0.990 \). All data were corrected against Gapdh as an internal control. Error bars represent SEM.

Alican blue and alizarin red staining. Skinned and eviscerated mouse carcases at P17 were fixed overnight in 95% ethanol and transferred to acetone. Fixed skeletons were stained in alizarin red and alcin blue, as described previously (88). Images were captured using an Olympus SP-570UZ digital camera. Skeletal elements from at least 4 different littermate pairs were imaged using a Zeiss Stereo Zoom Microscope Stemi SV6, and measurements of individual bones were undertaken with a ruler accurate to 0.1 mm.

microCT. Mice were euthanized on P17, skinned, eviscerated, and stored in formalin. Whole skeletons were scanned on a GE Locus Ultra scanner at 120 kV and 20 mA, with a 0.154-mm³ voxel resolution with a total of 900 slices per scan. To assess bone density, hind limbs were scanned on a GE Locus scanner at 80 kV and 0.450 mA with a 0.020-mm³ voxel resolution with 900 slices per scan. BMD, cortical thickness, and trabecular numbers were calculated using MicroView 3D visualization and analysis software (version 2.1.2, GE Healthcare Biosciences) (89). BMD was determined from proximal tibias using the bone analysis module within MicroView by defining the region of interest (ROI) as the area between 0.3 mm and 0.6 mm proximal to the growth plate to include the trabecular spongia. The ROI was a cylinder fitting within the central region of the trabecular bone, excluding the cortical bone. Cortical bone–mimicking epoxy (SB3, Gammex RMI) was used for calibration. Trabecular number was determined using the stereology function within MicroView, using the same ROI as used for BMD. Cortical thickness was determined at the tibial mid-diaphysis, defined as the distance halfway between the two ends of the tibia. Thickness of the bone was measured radially in each quadrant and averaged.

Picornavirus red staining of bone sections. Fore- and hind limbs were dissected at P0, P7, P10, and/or P17 upon sacrifice and processed for histological analyses by 0.1% picrosirius red (Sigma-Aldrich, catalog P6744-16A) as described previously (90). Trabecular area (mm²) within an area of interest (AOI) was measured by observers blinded to the experimental protocol using Openlab 4.0.4 software (Improvement), with the AOI set from just below the hypertrophic chondrocytes to 200 μm below the growth plate in the trabecular bone area of the mineralized zone. The AOI measurements were adapted from refs. 91, 92. Trabecular area was normalized to total AOI and expressed as a percentage. All images were taken with a Retiga EX camera (Leeds Precision Instruments Inc.) connected to a DMR2 microscope (Leica).

Ex vivo tibia cultures. Tibiae were isolated from P0 mutant and control mice using a Zeiss Stereo Zoom Microscope Stemi SV6 and dissection tools, as described previously (93). Isolated tibiae were plated in 12-well culture dishes and cultured with 1 ml per well of sterile organ culture α-MEM medium ( Gibco, Life Technologies, catalog 1257063) containing ascorbic acid (0.005%, Sigma-Aldrich, A4034), β-glycerophosphate (0.02%, Sigma-Aldrich, 819830), BSA (0.2%, Fisher Scientific, 9048486), 200 nM glutamine (0.25 ml, Gibco, Life Technologies, 25030081), and penicillin streptomycin (0.4 ml, Gibco, Life Technologies, 15140122) for 7 days at 37°C, 5% CO2. Organ culture medium was refreshed on days 2, 4, and 6. Tibia samples were fixed in 70% ethanol overnight at 4°C on day 7. Samples were processed, embedded in paraffin, and sectioned at the Molecular Pathology Core Facility, Robarts Research Institute, London, Ontario, Canada. Tibia lengths were measured on days 0 and 7 using the Zeiss Stereo Zoom Microscope Stemi SV6 with a ruler accurate to 0.1 mm.

Measurements of IGF-1, GH, T4, and glucose. Plasma and liver samples were collected from P17 mice. Blood was collected from the inferior vena cava. EDTA pH 7.0 was added to the blood sample and centrifuged at 21,000 × g for 10 minutes at 4°C. Plasma supernatant was collected and kept frozen at –80°C. Liver samples were collected and homogenized by 2 freeze-thaw cycles. Liver homogenate supernatant was collected and assayed immediately. Plasma and liver IGF-1 content were measured using a mouse IGF-1 ELISA kit (R&D Systems, catalog MG100). Plasma GH and T4 were assayed using Millipore (EZRMGH-45K) and Calbiotech (T4044T) ELISA kits, respectively, according to the manufacturers’ instructions. Blood glucose levels were measured immediately prior to sacrifice using the OneTouch FastTake Meter according to the manufacturer’s instructions.

Statistics. Statistical analysis was performed using GraphPad Prism software (4.02; GraphPad Software Inc.), and all results are expressed as the mean ± SEM unless indicated otherwise. Two independent data sets were compared with the Student’s t test (unpaired, 2-tailed). Statistical analyses of Kaplan-Meier survival curves were performed using the log-rank test and the Gehan-Breslow-Wilcoxon test. \( P \) values of 0.05 or less were considered to indicate significance.

Study approval. All procedures involving animals were conducted in accordance with the regulations of the Animals for Research Act of the Province of Ontario and approved by the University of Western Ontario Animal Care and Use Committee.

Acknowledgments
This work was supported by a Paediatrics Graduate Studentship at the University of Western Ontario, a Curtis Cadman Studentship, and a Queen Elizabeth II Ontario Graduate Scholarship in Science and Technology (QEIIOGSST) to L.A. Watson; a CIHR Masters Scholarship to J.R. Li; and an Ontario Graduate Scholarship to L.A. Solomon. Operating funds were from the Canadian Institutes for Health Research (CIHR-MOP93697 to N.G. Bérubé and CIHR-MOP102539 to N.G. Bérubé and F. Beier).

Received for publication July 9, 2012, and accepted in revised form February 14, 2013.

Address correspondence to: Nathalie G. Bérubé, Victoria Research Laboratories, 800 Commissioners Road East, London, Ontario, Canada N6C 2V5. Phone: 519.685.8500, ext. 55066; Fax: 519.685.8616; E-mail: nberube@uwo.ca.


77. Kim MY, Gleason-Guzman M, Izibicka E, Nishioka D, Hurley LH. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res. 2003;63(12):3247–3256.